{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"25"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"15"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"14"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"78"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"15"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"12"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"11"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"title":"Cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Cycle 16"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"title":"Cycle 19"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"8"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"title":"Cycle 22"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Cycle 25"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"title":"Cycle 28"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 31"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 34"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 37"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"title":"Cycle 40"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}],"title":"No Problem"},{"measurements":[{"groupId":"OG000","value":"19"}],"title":"Some Problem"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Extreme Problem"}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"description":"EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.","groups":[{"description":"Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.","id":"OG000","title":"Phase 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis was performed on PRO population. Here, 'number analyzed' = number of participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])","title":"Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Anxiety/Depression Scores at Specified Visits","type":"SECONDARY","unitOfMeasure":"Participants"}